clinical trials

Finerenone Meets Primary Endpoint in a Phase III cardiovascular outcomes study, Bayer recently announced the positive results from its Phase III FINEARTS-HF study, which evaluated the efficacy and safety of finerenone in patients with heart failure with mildly reduced...

Bayer's new drug application has submitted to the US FDA for elinzanetant. They disclosed this information in a statement on their website on August 1, 2024. They have submitted the new application targeting the treatment of moderate to severe...